Phase 3 Recruiting Network
This phase III trial studies how well lenalidomide and dexamethasone works with or without daratumumab in treating patients with high-risk smoldering myeloma. Drugs used in chemotherapy, such as lenalidomide and dexamethasone, work in diff…
Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT03937635
Locations: - University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
- Anchorage Associates in Radiation Medicine — Anchorage, Alaska
- Anchorage Radiation Therapy Center — Anchorage, Alaska
+ 738 more sites in the U.S.
Phase 3 Recruiting Network
This phase III trial compares the combination of four drugs (daratumumab, bortezomib, lenalidomide and dexamethasone) to the use of a three drug combination (daratumumab, lenalidomide and dexamethasone). Bortezomib may stop the growth of c…
Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT04566328
Locations: - Anchorage Associates in Radiation Medicine — Anchorage, Alaska
- Anchorage Radiation Therapy Center — Anchorage, Alaska
- Alaska Breast Care and Surgery LLC — Anchorage, Alaska
+ 639 more sites in the U.S.
Phase 3 Recruiting Network
This phase III trial compares three-drug induction regimens followed by double-or single-drug maintenance therapy for the treatment of newly diagnosed multiple myeloma in patients who are not receiving a stem cell transplant and are consid…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT05561387
Locations: - Anchorage Associates in Radiation Medicine — Anchorage, Alaska
- Anchorage Radiation Therapy Center — Anchorage, Alaska
- Alaska Breast Care and Surgery LLC — Anchorage, Alaska
+ 394 more sites in the U.S.
Phase 3 Recruiting Industry
The purpose of this study is to learn about the study medicine called elranatamab.This study aims to compare elranatamab to other medicines for the treatment of MM (a type of cancer). This study is seeking participants who: * Are 18 years …
Sponsor: Pfizer
NCT ID: NCT06152575
Locations: - Infirmary Cancer Care — Mobile, Alabama
- Western Regional Medical Center, Inc. dba. City of Hope Phoenix — Goodyear, Arizona
- Beverly Hills Cancer Center — Beverly Hills, California
+ 98 more sites in the U.S.
Phase 3 Recruiting Industry
The purpose of this study is to compare the efficacy of teclistamab in combination with daratumumab and lenalidomide (Tec-DR) and talquetamab in combination with daratumumab and lenalidomide (Tal-DR) versus daratumumab, lenalidomide, dexam…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT05552222
Locations: - Banner MD Anderson Cancer Center — Gilbert, Arizona
- University of Arizona Cancer Center — Tucson, Arizona
- UCSF Fresno — Clovis, California
+ 64 more sites in the U.S.
Phase 3 Recruiting Industry
The purpose of this study is to compare the efficacy and safety of mezigdomide (CC-92480), bortezomib and dexamethasone (MeziVd) versus pomalidomide, bortezomib and dexamethasone (PVd) in participants with relapsed or refractory multiple m…
Sponsor: Celgene
NCT ID: NCT05519085
Locations: - Local Institution - 0366 — Los Alamitos, California
- Local Institution - 0272 — San Diego, California
- Local Institution - 0273 — West Hollywood, California
+ 53 more sites in the U.S.
Phase 3 Recruiting Industry
The purpose of this study is to compare the effectiveness of either talquetamab plus pomalidomide (Tal-P) or talquetamab plus teclistamab (Tal-Tec) with elotuzumab, pomalidomide, and dexamethasone (EPd) or pomalidomide, bortezomib, and dex…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT06208150
Locations: - UCSF Fresno — Clovis, California
- UCLA — Santa Monica, California
- Yale University School Of Medicine — New Haven, Connecticut
+ 46 more sites in the U.S.
Phase 3 Recruiting Industry
This is a randomised, multicentre, controlled, open-label, Phase III global study comparing the efficacy and safety of AZD0120 versus standard regimens (DKd \[daratumumab, carfilzomib, and dexamethasone\], DPd \[daratumumab, pomalidomide, …
Sponsor: AstraZeneca
NCT ID: NCT07391657
Locations: - Research Site — Gilbert, Arizona
- Research Site — Phoenix, Arizona
- Research Site — Tucson, Arizona
+ 45 more sites in the U.S.
Phase 3 Recruiting Industry
Multiple myeloma (MM) is a cancer of the blood's plasma cells. The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, and kidney fail…
Sponsor: AbbVie
NCT ID: NCT06158841
Locations: - University of Alabama at Birmingham - Main /ID# 261434 — Birmingham, Alabama
- Mayo Clinic Hospital - Phoenix /ID# 263326 — Phoenix, Arizona
- Alta Bates Summit Medical Center for Research /ID# 261438 — Berkeley, California
+ 43 more sites in the U.S.
Phase 3 Recruiting Network
This is a multicenter, randomized, open-label, Phase 3 study in participants with newly diagnosed multiple myeloma to evaluate the benefits of teclistamab in combination with lenalidomide and teclistamab alone versus lenalidomide alone as …
Sponsor: European Myeloma Network B.V.
NCT ID: NCT05243797
Locations: - Banner University Medical Center Tucson, University of Arizona — Phoenix, Arizona
- UCLA Medical Center — Los Angeles, California
- University of California-Davis Cancer Center — Sacramento, California
+ 39 more sites in the U.S.
Phase 3 Recruiting Industry
The purpose of this Phase 3 study is to evaluate if BRd prolongs progression free survival (PFS) and/or improves minimal residual disease (MRD) negative status compared with DRd in participants with TI-NDMM.
Sponsor: GlaxoSmithKline
NCT ID: NCT06679101
Locations: - GSK Investigational Site — Mobile, Alabama
- GSK Investigational Site — Phoenix, Arizona
- GSK Investigational Site — Beverly Hills, California
+ 27 more sites in the U.S.
Phase 3 Recruiting Industry
The purpose of this study is to evaluate how well JNJ-79635322 works when compared with an anti-B-cell maturation antigen (BCMA)xCD3 bispecific antibody.
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT07258511
Locations: - UAMS — Little Rock, Arkansas
- USC Norris Comprehensive Cancer Center — Los Angeles, California
- University of California San Francisco — San Francisco, California
+ 25 more sites in the U.S.